SCHEMBL7450197

SCHEMBL7450197

COc1[c]nccc1-c1ccccn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.42
LMNA P02545 7/20 0.42
CCR1 P32246 2/20 0.42
CCR5 P51681 2/20 0.42
CCR8 P51685 2/20 0.42
POLB P06746 2/20 0.42
CYP1A2 P05177 1/20 0.42
METAP1 P53582 1/20 0.42
BLM P54132 1/20 0.42
HIF1A Q16665 1/20 0.42
DOHH Q9BU89 1/20 0.42
P4HTM Q9NXG6 1/20 0.42
SMN1; SMN2 Q16637 10/20 0.41
TP53 P04637 5/20 0.41
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
PKM P14618 3/20 0.41
GAA P10253 2/20 0.41
HSD17B10 Q99714 2/20 0.41
TDP1 Q9NUW8 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7453259 0.81 CLK4 (0.40) KDM4ELMNACYP1A2SMN1; SMN2TP53
SCHEMBL6787273 0.77 KDM4E (0.47) KDM4ELMNACCR1CCR5CCR8
SCHEMBL11695494 0.77 KDM4E (0.46) KDM4ELMNACCR1CCR5CCR8
SCHEMBL9534293 0.75 KDM4E (0.48) KDM4ELMNACCR1CCR5CCR8
SCHEMBL16569092 0.74 CYP2A6 (0.39) KDM4ESMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL1641797 0.74 KDM4E (0.46) KDM4ELMNACCR1CCR5CCR8
SCHEMBL7446349 0.73 KDM4E (0.42) KDM4ELMNACCR1CCR5CCR8
SCHEMBL558146 0.73 SMN1; SMN2 (0.46) KDM4ELMNACCR1CCR5CCR8
SCHEMBL7221022 0.73 KDM4E (0.49) KDM4ELMNAMETAP1BLMTP53
SCHEMBL18953142 0.71 KDM4E (0.39) KDM4ELMNACCR1CCR5CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020061877-A1 Substituted cyclic amine metalloprotease inhibitors THE PROCTER & GAMBLE COMPANY 2002-05-23 US disclosed
EP-1104403-A1 HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS Pfizer Products Inc. (US) 2001-06-06 EP disclosed
WO-2000009485-A1 HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS PFIZER PRODUCTS INC. (US) 2000-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061877-A1 Substituted cyclic amine metalloprotease inhibitors CMA1, ADAM17, MMP25 KDM4E 1477/4885LMNA 1618/4885CCR1 1092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.